Floatz logo

Dextromethorphan

Renal Impairment

CelgeneSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Renal Impairment cohort.

Asset / SponsorPhaseRating
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
Pomalidomide
Hellenic Society of Hematology
Phase 2B
RANITIDINE
Hellenic Society of Hematology
Phase 2CCC
Benadryl
Hellenic Society of Hematology
Phase 2CCC
Isatuximab
Hellenic Society of Hematology
Phase 2CCC

View all 15 →

Same molecule, other indications

Dextromethorphan is also rated in:

Pseudobulbar Affect (PBA)Dormant
BBB
Indicative ·
75 / 100
View asset →
stroke disorderDormant
BBB
Indicative ·
73 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →